Sclerosis News and Research

RSS

Fumaric acid salts may protect against Multiple Sclerosis

Fumaric acid salts have been in use against severe psoriasis for a long time. About ten years ago, researchers in Bochum speculated that they may also have a favourable effect on Multiple Sclerosis as a result of their TH2 polarizing mechanisms.

8 Mar 2011

hUCBs and MenSCs transplant may offer future therapeutic benefit for AD, stroke, ALS

Transplanting stem cells derived from umbilical cord blood cells and menstrual blood cells may offer future therapeutic benefit for those suffering from stroke, Alzheimer's disease, and amyotrophic lateral sclerosis, says a team of neuroscience researchers from the University of South Florida's Department of Neurosurgery and Brain Repair and collaborators from three private-sector research groups, Saneron CCEL Therapeutics, Inc., Tampa, FL, Cryo-Cell International, Inc., Oldsmar, FL, and Cryopraxis, Cell Praxis, BioRio, Rio de Janeiro, Brazil.

8 Mar 2011

Efficient medical treatments to be showcased at SIR's 36th Annual Scientific Meeting

The Society of Interventional Radiology will feature minimally invasive scientific advances and new discoveries in treating a host of diseases at its 36th Annual Scientific Meeting March 26–31 at McCormick Place (West) in Chicago, Ill. The theme of the meeting is "IR Rising: Leading Image-guided Medicine," chosen to reflect interventional radiology's continued revolutionizing of modern medicine.

5 Mar 2011

Scientists detail role of TDP-43 in ALS pathology

Amyotrophic lateral sclerosis, known as ALS or more popularly, Lou Gehrig's disease, is a notorious neurodegenerative condition characterized by the progressive deterioration of brain and spinal cord neurons, resulting in the gradual but catastrophic loss of muscle control and ultimately, death.

5 Mar 2011

Electrical stimulation may help bring back the voice of stroke patients

A Virginia Tech College of Engineering researcher is seeking a new way to help those who are unable to speak to find their voice. But this isn't "The King's Speech," the Academy Award-winning film about a British royal undergoing speech therapy to battle a stammer. Instead, Alexander Leonessa wants to help bring back the voice of stroke patients and others who have suffered paralysis of the vocal folds, through electrical stimulation.

4 Mar 2011

Neurodegenerative Disease Management – meeting the challenge of neurodegenerative diseases

Future Medicine Ltd has today announced the launch of Neurodegenerative Disease Management – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world.

3 Mar 2011

New research provides insight into link between sunlight, vitamin D3, MS risk and severity

New research into the neurodegenerative disease, Multiple Sclerosis offers new insight into the link between sunlight, vitamin D3, and MS risk and severity.

3 Mar 2011

Viruses that are natural part of human genome may retrovirus culprit

A retrovirus that inserted itself into the human genome thousands of years ago may be responsible for some cases of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gherig’s disease. The finding, made by Johns Hopkins scientists, may eventually give researchers a new way to attack this universally fatal condition.

2 Mar 2011

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS).

2 Mar 2011

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, today announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis.

1 Mar 2011

Cryo-Cell fiscal 2010 net income increases to $3.4 million

Cryo-Cell International, Inc., one of the world's largest and most established family cord blood banks and an industry leader of innovative stem cell solutions, today announced results for its fiscal year 2010.

28 Feb 2011

BrainStorm raises $3.6 million through private placement financing

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing in reliance upon Regulation S. BrainStorm received gross proceeds of approximately $3.6 million resulting from the sale of shares at a purchase price of $0.28 per share at the closing of the transaction.

28 Feb 2011

Study findings support therapeutic approach for common form of MS

In an effort to develop therapeutic remedies for multiple sclerosis, scientists debate two possible interventional approaches - but they're on opposite sides of the spectrum. Researchers at Wayne State University's School of Medicine, however, have reached a definitive conclusion as to which approach is correct, putting an end to a long-disputed issue.

24 Feb 2011

New research: Alzheimer's disease may be easily misdiagnosed in elder people

New research shows that Alzheimer's disease and other dementing illnesses may be easily misdiagnosed in the elderly, according to early results of a study of people in Hawaii who had their brains autopsied after death. The research is being released today and will be presented as part of a plenary session at the American Academy of Neurology's 63rd Annual Meeting in Honolulu April 9 to April 16, 2011.

23 Feb 2011

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Aestus Therapeutics, Inc., announced today that it has initiated screening of patients for a clinical trial to evaluate the efficacy of its novel pain therapeutic, ATx08-001. This placebo-controlled, two-dose level study will test the efficacy of ATx08-001 in reducing the pain following an outbreak of shingles.

23 Feb 2011

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

A strategy developed by Massachusetts General Hospital (MGH) researchers to shield the ovaries of female mammals from the damaging effects of radiation and chemotherapy has passed an important milestone. A collaborative study with investigators from Oregon Health and Sciences University (OHSU), published online in the journal Fertility and Sterility, reports that brief preexposure of the ovaries to an FDA-approved agent called FTY720 preserved the fertility of female rhesus monkeys exposed to potentially lethal doses of radiation.

23 Feb 2011

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Harbor BioSciences, Inc., which is investigating the use the company's proprietary compound Triolex as a treatment for Parkinson's disease with funding from The Michael J. Fox Foundation, announced positive results in initial preclinical studies.

23 Feb 2011

Higher intake of vitamin D may reduce breast cancer risk

Researchers at the University of California, San Diego School of Medicine and Creighton University School of Medicine in Omaha have reported that markedly higher intake of vitamin D is needed to reach blood levels that can prevent or markedly cut the incidence of breast cancer and several other major diseases than had been originally thought. The findings are published February 21 in the journal Anticancer Research.

23 Feb 2011

Research shows possible link between warm weather and cognition in people with MS

People with multiple sclerosis may find it harder to learn, remember or process information on warmer days of the year, according to new research released today that will be presented at the American Academy of Neurology's 63rd Annual Meeting in Honolulu April 9 to April 16, 2011.

18 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

Sclerosis News and Research

Fumaric acid salts may protect against Multiple Sclerosis

hUCBs and MenSCs transplant may offer future therapeutic benefit for AD, stroke, ALS

Efficient medical treatments to be showcased at SIR's 36th Annual Scientific Meeting

Scientists detail role of TDP-43 in ALS pathology

Electrical stimulation may help bring back the voice of stroke patients

Neurodegenerative Disease Management – meeting the challenge of neurodegenerative diseases

New research provides insight into link between sunlight, vitamin D3, MS risk and severity

Viruses that are natural part of human genome may retrovirus culprit

EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis

Bayhill's BHT-3034 receives FDA IND clearance for treatment of myasthenia gravis

Cryo-Cell fiscal 2010 net income increases to $3.4 million

BrainStorm raises $3.6 million through private placement financing

Study findings support therapeutic approach for common form of MS

New research: Alzheimer's disease may be easily misdiagnosed in elder people

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Higher intake of vitamin D may reduce breast cancer risk

Research shows possible link between warm weather and cognition in people with MS

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News